Mounjaro Vs Saxenda - Guide | Cured Pharmacy

Mounjaro Vs Saxenda

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

Featured Product

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

From £145.00£124.99UK-based prescribers · Discreet delivery · Free private prescription
Start Assessment →✓ Lowest price guarantee
DISCOUNT CODE: FIRST20

£20 off for new patients

Tarun Kumar, Prescribing Pharmacist at Cured Pharmacy

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: 17 June 2026

Last Updated: 12 August 2026

If you have been researching weight loss injections in the UK, you have almost certainly come across two names that keep appearing at the top of every comparison list: Mounjaro and Saxenda. Both are prescription-only injectable medications designed to help people with obesity or weight-related health conditions lose weight, but they work in quite different ways and produce noticeably different results. Choosing between them can feel genuinely overwhelming, especially when you are already dealing with the emotional and physical challenges that come with managing your weight.

Quick Summary

Both Mounjaro (tirzepatide) and Saxenda (liraglutide) are licensed weight loss injections available in the UK, but they differ significantly in how they work, how much weight you can expect to lose, how often you inject, and how much they cost. In 2026, clinical evidence continues to support Mounjaro as the more powerful option for most adults seeking significant weight reduction.

  • Mounjaro is a dual GIP and GLP-1 receptor agonist; Saxenda acts on GLP-1 receptors only
  • Clinical trials show Mounjaro can deliver up to 22.5% body weight loss versus approximately 8% with Saxenda
  • Mounjaro is injected once weekly; Saxenda requires a daily injection
  • Both medications require a valid prescription from a qualified UK prescriber
  • Side effects for both are largely gastrointestinal, including nausea, vomiting, and diarrhoea

Weight Loss Timeline Estimator

Enter your details to estimate your potential weight loss timeline with Mounjaro or Saxenda.

Table of Contents

  1. How Mounjaro and Saxenda Work Differently in the Body
  2. Comparing Weight Loss Results: What the Clinical Evidence Shows
  3. Side Effects and Tolerability: What to Expect From Each Medication
  4. Dosing Schedule and Convenience: Weekly vs Daily Injections
  5. Cost, Availability, and Access in the UK
  6. Who Is Each Medication Suitable For?
  7. Full Head-to-Head Comparison Table
  8. Key Takeaways
  9. When to Seek Professional Advice
  10. Scientific References
  11. FAQs

How Mounjaro and Saxenda Work Differently in the Body

To understand the Mounjaro vs Saxenda comparison properly, it helps to start with the fundamental science. These are not simply two versions of the same drug. They are built on entirely different pharmacological principles, which explains why their results can be so strikingly different.

Saxenda contains liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a hormone naturally released by your gut after eating. It tells your brain you are full, slows down the emptying of your stomach, and stimulates insulin release from the pancreas. By mimicking this hormone, Saxenda helps reduce appetite and slows food intake. Saxenda was originally developed from the diabetes drug Victoza and has been used for weight management since it received its UK licence in 2015.

Mounjaro, on the other hand, contains tirzepatide and represents an entirely new class of medication. It is a dual GIP and GLP-1 receptor agonist, meaning it activates two separate hormonal pathways simultaneously. GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone that works alongside GLP-1 to reduce appetite and enhance insulin sensitivity. This dual action is why Mounjaro produces substantially greater weight loss than Saxenda in the majority of clinical comparisons.

Both medications are given by subcutaneous injection — meaning they are injected under the skin — and both slow gastric emptying, reduce caloric intake, and improve satiety signals in the brain. However, Mounjaro's twin hormonal mechanism gives it a meaningful advantage in terms of the overall metabolic impact it delivers.

  • Saxenda acts on GLP-1 receptors only — a single hormonal pathway
  • Mounjaro activates both GIP and GLP-1 receptors simultaneously
  • Both medications reduce appetite and slow gastric emptying
  • Tirzepatide's dual action produces greater insulin sensitivity improvements
  • Neither medication is a substitute for a healthy diet and regular physical activity

Comparing Weight Loss Results: What the Clinical Evidence Shows

When it comes to real-world results, the difference between these two medications is quite significant. People comparing Mounjaro vs Saxenda in clinical settings have consistently found tirzepatide to be the more powerful weight loss agent. The landmark SURMOUNT-1 trial, published in the New England Journal of Medicine, demonstrated that participants taking tirzepatide at the 15mg dose lost an average of 22.5% of their body weight over 72 weeks — equivalent to roughly 23kg in someone starting at 100kg.

By comparison, the SCALE Obesity and Prediabetes trial for Saxenda showed an average weight loss of approximately 8% of body weight over 56 weeks in non-diabetic participants. That is still a clinically meaningful result — losing 8kg if you start at 100kg would significantly improve blood pressure, cholesterol, and blood sugar levels — but it is considerably less than what Mounjaro routinely delivers.

It is important to be honest here: not everyone achieves these average results. Weight loss medication works best when combined with a reduced-calorie diet and increased physical activity. Some people on Saxenda lose more than 8%, and some people on Mounjaro lose less than 20%. However, the clinical trial data is clear and reproducible — tirzepatide is a more effective weight loss agent across most patient populations studied to date in 2026.

If you are looking to complement your weight loss journey with additional support, XLS Medical Weight Loss Plus tablets are a popular OTC option that some people use alongside lifestyle changes. However, for more significant weight reduction, prescription injections remain the gold standard approach.

  • Mounjaro achieves up to 22.5% body weight loss at the highest 15mg dose
  • Saxenda typically delivers 5–8% body weight loss in most clinical populations
  • Mounjaro's superiority is consistent across multiple large-scale clinical trials
  • Both medications perform better when paired with dietary changes and exercise
  • Response to treatment varies between individuals regardless of which medication is chosen

Side Effects and Tolerability: What to Expect From Each Medication

Side effects are one of the most commonly searched aspects of the Mounjaro vs Saxenda debate, and it is a completely valid concern. Starting any injectable medication can feel daunting, so it is helpful to know what you might experience and how the two medications compare in terms of tolerability.

Both Mounjaro and Saxenda share a broadly similar side effect profile, largely because both act on the GLP-1 pathway. The most common side effects for both include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. These effects tend to be worst in the first few weeks of treatment and during dose escalation stages. Most people find that symptoms improve significantly once their body has adjusted to the medication.

With Saxenda, because doses are escalated daily over a period of weeks, some people find the nausea manageable from the outset. However, others experience quite pronounced side effects, particularly around the 1.8mg and 2.4mg daily dose stages. With Mounjaro, the weekly dose escalation schedule is slightly more gradual in terms of frequency, but because the medication is ultimately more potent, some individuals experience more pronounced gastrointestinal effects at higher doses.

Rare but serious risks for both medications include pancreatitis, gallbladder problems, and — in animal studies — thyroid C-cell tumours. These risks are considered very low in clinical practice and both medications carry clear contraindications in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

  • Nausea is the most commonly reported side effect for both Mounjaro and Saxenda
  • Side effects typically peak during dose escalation and then subside
  • Injection site reactions (redness, bruising) can occur with both medications
  • Both medications are contraindicated in pregnancy
  • Pancreatitis is a rare but serious risk — stop the medication and seek medical help immediately if you experience sudden, severe abdominal pain

Dosing Schedule and Convenience: Weekly vs Daily Injections

One of the most practically important differences in the Mounjaro vs Saxenda comparison is the dosing schedule. For many patients, the frequency of injections is a deciding factor in which medication they prefer — and this is entirely reasonable. Medication adherence is significantly improved when treatment is convenient and fits naturally into daily life.

Saxenda is injected once daily at any time of day, with or without food. The dose starts at 0.6mg per day for the first week, then escalates in weekly 0.6mg increments until the maintenance dose of 3mg per day is reached after approximately five weeks. This gradual titration is designed to minimise side effects, but it does mean you are committing to a daily injection indefinitely — which some people find burdensome over time.

Mounjaro is injected just once a week, on the same day each week if possible. The starting dose is 2.5mg weekly for four weeks, followed by an increase to 5mg, 7.5mg, 10mg, 12.5mg, and ultimately 15mg over several months. Many patients find that the once-weekly dosing schedule is significantly more manageable and easier to incorporate into their routine, which supports better long-term adherence and ultimately better outcomes.

The KwikPen device used for Mounjaro is also frequently cited by patients as being particularly easy to use. It is pre-filled, pre-dosed, and does not require any manual dose dialling, making it accessible even for people who feel anxious about injections.

  • Saxenda requires a daily injection; Mounjaro requires only a once-weekly injection
  • Mounjaro's KwikPen device is pre-filled and straightforward to use
  • Both can be injected into the abdomen, thigh, or upper arm
  • Missed doses should be managed differently — always read the patient information leaflet
  • Weekly dosing with Mounjaro is associated with higher patient satisfaction scores in real-world surveys

Cost, Availability, and Access in the UK

Cost is a very real consideration for many people exploring weight loss injections in the UK. Neither Mounjaro nor Saxenda is currently available on the NHS for the majority of weight loss patients, meaning most people access these medications through private prescription routes.

Saxenda has been available in the UK for longer and is generally slightly less expensive per month than Mounjaro when comparing headline costs. A monthly supply of Saxenda (five pre-filled pens) typically costs between £150 and £200 depending on the supplier, while Mounjaro's monthly cost varies between approximately £140 and £250 depending on the dose tier. However, because Mounjaro produces faster and more significant weight loss, some healthcare economists argue it offers better value per kilogram lost.

Cured Pharmacy offers Mounjaro Weight Loss Injections starting from From £145.00£124.99, with a free private prescription included and discreet delivery to your door from UK-based prescribers. If you are comparing the longer-term cost of treatment, it is worth factoring in that many people reach their weight loss goals with Mounjaro faster, which may mean a shorter overall treatment duration compared to Saxenda.

For those who prefer non-prescription weight management support alongside their treatment, the XLS Medical Direct Fat Binder is available without a prescription and may offer supplementary support for some individuals.

  • Neither Mounjaro nor Saxenda is routinely available on NHS for weight loss as of 2026
  • Private prescription costs for both medications typically range from £145–£250 per month
  • Mounjaro may offer better cost-per-kg-lost value due to superior efficacy
  • Online prescribing services make access more straightforward than ever before
  • Always ensure you access these medications through a legitimate, GPhC-registered UK pharmacy

Who Is Each Medication Suitable For?

Understanding eligibility criteria is critical when weighing up Mounjaro vs Saxenda. Both medications are intended for adults — not children or adolescents — and both have specific body mass index (BMI) and health condition criteria that must be met before they can be prescribed.

Saxenda is licensed for adults with a BMI of 30 or above, or a BMI of 27 or above if they also have at least one weight-related comorbidity such as type 2 diabetes, hypertension, or high cholesterol. Mounjaro carries the same broad eligibility criteria in the UK — a BMI of 30 or more, or 27 or more with at least one weight-related health condition.

However, there are important contraindications to be aware of for both. Neither medication should be used in pregnancy or breastfeeding. Both should be avoided in people with a personal or family history of medullary thyroid carcinoma. People with severe gastrointestinal conditions such as gastroparesis should speak to their prescriber before starting either treatment. Saxenda is specifically licensed for type 2 diabetes management in some countries, while Mounjaro (tirzepatide) was originally developed as a diabetes medication under the brand name Mounjaro before receiving its specific weight management licence.

For people who are not suitable candidates for injectable weight loss medications, oral options such as Orlos (Orlistat) 60mg Weight Loss Aid capsules or Alli Weight Loss Capsules 60mg represent licensed OTC alternatives that work by blocking the absorption of dietary fat.

  • Both medications require a BMI of 30+ or 27+ with a weight-related health condition
  • Neither is suitable for use during pregnancy or breastfeeding
  • People with a history of pancreatitis should discuss risks carefully with their prescriber
  • Mounjaro may be particularly well suited to people who also have type 2 diabetes or insulin resistance
  • Saxenda may be considered where Mounjaro is contraindicated or where lower dose escalation is preferred

Full Head-to-Head Comparison Table

Feature Mounjaro (Tirzepatide) Saxenda (Liraglutide)
Active ingredient Tirzepatide Liraglutide
Mechanism of action Dual GIP and GLP-1 receptor agonist GLP-1 receptor agonist only
Injection frequency Once weekly Once daily
Starting dose 2.5mg weekly 0.6mg daily
Maximum maintenance dose 15mg weekly 3mg daily
Average weight loss (clinical trials) Up to 22.5% body weight Approximately 5–8% body weight
Common side effects Nausea, vomiting, diarrhoea, constipation Nausea, vomiting, diarrhoea, constipation
UK licence for weight management Yes (MHRA approved) Yes (MHRA approved)
Approximate monthly cost (private) From From £145.00£124.99 Approximately £150–£200
Suitable for type 2 diabetes Yes Yes (with separate dosing licence)
Delivery device Pre-filled KwikPen Pre-filled injection pen
NHS availability for weight loss Limited — primarily private in 2026 Limited — primarily private in 2026

Key Takeaways

  • Mounjaro (tirzepatide) is a dual-action GIP and GLP-1 receptor agonist that produces substantially greater weight loss than Saxenda (liraglutide) in clinical trials — up to 22.5% versus approximately 8% of body weight
  • Mounjaro is dosed once weekly while Saxenda requires a daily injection, making Mounjaro considerably more convenient for most people
  • Both medications share a similar gastrointestinal side effect profile, with nausea being the most commonly reported complaint during dose escalation
  • Neither medication is widely available on the NHS for weight loss in 2026, but both can be accessed through legitimate UK private prescribing services like Cured Pharmacy
  • For most eligible adults seeking meaningful, sustained weight loss, Mounjaro currently represents the stronger clinical choice — though individual suitability must always be assessed by a qualified prescriber

When to Seek Professional Advice

Before starting either Mounjaro or Saxenda, it is essential to speak with a qualified prescriber who can assess your full medical history, current medications, and individual suitability. You should seek professional advice promptly if you experience any of the following during treatment:

  • Sudden, severe abdominal pain that radiates to your back — this could indicate pancreatitis
  • Signs of a serious allergic reaction, including swelling of the face, lips, or throat, or difficulty breathing
  • Symptoms of gallbladder problems, such as upper-right abdominal pain, fever, or jaundice
  • A lump or swelling in your neck, or persistent hoarseness — this could indicate thyroid issues
  • Unexplained changes in heart rate, vision problems, or signs of dehydration due to severe vomiting or diarrhoea

Never stop or change your dose of either medication without speaking to your prescriber first. If you are unsure whether you are suitable for prescription weight loss injections, a short online consultation with a UK prescriber is the safest and most effective starting point.

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today.

Once you complete a short online assessment, you will be able to choose your preferred treatment and quantity from a list of safe, medically approved options tailored to you.

Start My AssessmentReturning Customer?Log In to Your Account

Scientific References

  1. Jastreboff AM et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. SURMOUNT-1 Trial. [Accessed 12 August 2026]
  2. Pi-Sunyer X et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. SCALE Obesity and Prediabetes Trial (published via The Lancet affiliated journals). [Accessed 12 August 2026]
  3. National Institute for Health and Care Excellence (NICE). (2023). Tirzepatide for managing overweight and obesity. Technology appraisal guidance TA875. NICE.org.uk. [Accessed 12 August 2026]
  4. NICE Technology Appraisal TA875: Tirzepatide for managing overweight and obesity, NICE, 2023 [Accessed 12 August 2026]
  5. NICE Technology Appraisal TA664: Liraglutide for managing overweight and obesity, NICE, 2020 [Accessed 12 August 2026]
  6. Mounjaro (tirzepatide) Summary of Product Characteristics, Electronic Medicines Compendium (EMC), Eli Lilly, 2023 [Accessed 12 August 2026]
  7. Saxenda (liraglutide 3 mg) Summary of Product Characteristics, Electronic Medicines Compendium (EMC), Novo Nordisk, 2023 [Accessed 12 August 2026]
  8. Jastreboff AM et al., Tirzepatide Once Weekly for the Treatment of Obesity, The Lancet, 2022 [Accessed 12 August 2026]
  9. Diabetes UK evidence-based nutrition guidelines and weight management recommendations for adults with type 2 diabetes, Diabetes UK, 2023 [Accessed 12 August 2026]

Frequently Asked Questions

How long does it take to see results with Mounjaro vs Saxenda?

Results with Mounjaro vs Saxenda differ noticeably in timeline. Mounjaro users often report visible weight loss within the first four to eight weeks, while Saxenda users typically begin noticing changes after eight to twelve weeks. Both medications require consistent use alongside lifestyle changes to achieve meaningful, sustained weight loss results.

Is Mounjaro safer than Saxenda for long-term use?

Mounjaro and Saxenda both carry acceptable safety profiles for long-term use when prescribed appropriately. Mounjaro's dual-action mechanism produces superior weight loss results in clinical trials, but both are approved by the MHRA. Your prescriber will assess your individual health history before recommending the most suitable option for you.

Can you switch from Saxenda to Mounjaro?

Yes, you can switch from Saxenda to Mounjaro, but this should always be done under the supervision of a qualified prescriber. A clinical review is required to assess your current progress, tolerability, and medical suitability before transitioning between these two different weight loss injection medications safely.

What is the dose of Mounjaro compared to Saxenda?

The dose of Mounjaro starts at 2.5mg once weekly, increasing up to 15mg weekly over several months. Saxenda starts at 0.6mg daily, escalating to a maintenance dose of 3mg per day. Mounjaro is dosed weekly which many patients find more convenient than Saxenda's daily injection schedule.

Back to blog